Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany; Pharmaceutical Research Associates (PRA) Health Sciences, Mannheim, Germany.
Cancer Treat Rev. 2018 Mar;64:30-39. doi: 10.1016/j.ctrv.2018.02.003. Epub 2018 Feb 10.
Colorectal cancer (CRC) is largely diagnosed at old age, when comorbidities and frailty are common and might be important prognostic factors of CRC. We aimed to systematically review epidemiological evidence on the prognostic role of comorbidity and frailty in CRC patients.
We systematically searched the PubMed and Web of Science databases up to August 08, 2017 for observational studies that used a standardized index to assess comorbidity or frailty, investigated and reported odds ratios (OR) or hazard ratios (HR) of their associations with any of the following CRC prognostic outcomes: thirty-day, overall or CRC-specific mortality and disease-free or recurrence-free survival. The study was conducted using standard meta-analysis methodology.
Thirty-seven cohort studies were identified and included in this review: 35 on comorbidity and 2 on frailty. Of the 35 studies, 13 with comparable methodology were eligible for a meta-analysis. Compared to CRC patients without comorbidity, those with mild/moderate and severe comorbidity had, respectively, a higher risk of 30-day (OR = 1.71; 95% confidence interval (CI): 1.26-2.31 and OR = 2.62; 95% CI: 1.97-3.47), overall (HR = 1.41; 95% CI: 1.23-1.62 and HR = 2.03; 95% CI: 1.76-2.34), and CRC-specific mortality (HR = 1.06; 95% CI: 1.02-1.10 and HR = 1.14; 95% CI: 1.04-1.23). Frail CRC patients showed higher overall mortality than non-frail patients (HR: 2.60-3.39).
Comorbidity and frailty are strong prognostic factors of survival in CRC patients apart from the commonly considered sociodemographic and tumor characteristics. Comprehensive geriatric assessment might help to optimize care of CRC patients, by improving early identification and management of comorbidities and geriatric syndromes.
结直肠癌(CRC)主要在老年时被诊断出来,此时合并症和虚弱很常见,并且可能是 CRC 的重要预后因素。我们旨在系统地综述合并症和虚弱对 CRC 患者预后影响的流行病学证据。
我们系统地检索了 PubMed 和 Web of Science 数据库,截至 2017 年 8 月 8 日,以寻找使用标准化指标评估合并症或虚弱的观察性研究,并调查和报告其与以下任何 CRC 预后结局相关的比值比(OR)或风险比(HR):30 天、总生存期或 CRC 特异性死亡率,以及无病或无复发生存率。研究采用标准的荟萃分析方法进行。
共确定并纳入了 37 项队列研究:35 项关于合并症,2 项关于虚弱。在 35 项研究中,有 13 项具有可比性的方法学研究纳入荟萃分析。与无合并症的 CRC 患者相比,有轻度/中度和重度合并症的患者,30 天(OR=1.71;95%置信区间(CI):1.26-2.31 和 OR=2.62;95%CI:1.97-3.47)、总生存期(HR=1.41;95%CI:1.23-1.62 和 HR=2.03;95%CI:1.76-2.34)和 CRC 特异性死亡率(HR=1.06;95%CI:1.02-1.10 和 HR=1.14;95%CI:1.04-1.23)的风险更高。虚弱的 CRC 患者的总死亡率高于非虚弱患者(HR:2.60-3.39)。
除了常见的社会人口学和肿瘤特征外,合并症和虚弱是 CRC 患者生存的强有力预后因素。综合老年评估可能有助于通过改善合并症和老年综合征的早期识别和管理,来优化 CRC 患者的治疗。